- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Sep 8, 2021
Deals
Like a ROCK: Sanofi takes out Kadmon for $1.9B, gains transplant drug
Takeout of the Waksal-led biotech comes on the heels of the approval of the company’s ROCK2 inhibitor for GvHD
BioCentury | Mar 28, 2016
Strategy
Canbridge can-can
Why Aveo's AV-203 is leading Canbridge to venture outside Asia
BioCentury | Feb 17, 2014
Emerging Company Profile
Canbridge: A bridge to China
Genzyme alumni at Canbridge in-licensing Western programs to develop in China
BioCentury | Feb 21, 2011
Strategy
BioMarin wants control
BioMarin, sanofi in talks to determine future of rights to Aldurazyme
BioCentury | Oct 25, 2010
Finance
Argument for $89
Genzyme itemizes why it's worth $89 a share, not $69 bid by sanofi-aventis
BioCentury | Jun 21, 2010
Strategy
Playing Brazil
Beyond generics: Strategies for growing innovator drug sales in Brazil
Items per page:
1 - 10 of 120